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SUMMARY  Psoriasis is a complex disease that requires safe, long-
term treatment. Topical steroid therapy, topical non-steroid therapy 
only, and a combination of various topical therapies in the treatment 
of mild to moderate forms of psoriasis are presented. Topical 
therapy includes corticosteroids, vitamin D3 analogs, retinoids, 
tars, anthralin, keratolytics, and topical immunomodulators. While 
most medications are approved for use as a single agent in the 
treatment of psoriasis, some of these drugs are most effective when 
used in combination with topical corticosteroids. Topical therapy is 
generally administered for mild and localized forms of psoriasis, 
whereas phototherapy and systemic therapy are reserved for 
extensive lesions and more severe forms of the disease. Individual 
approach is absolutely necessary in each patient with psoriasis.
KEY WORDS: topical glucocorticosteroids; adverse effects of 
topical corticosteroids; psoriasis
INTRODUCTION
 Psoriasis is considered to be a genetically 
caused, chronic relapsing and inflammatory dis-
ease that involves the skin, the scalp and the 
joints. Psoriasis is now considered to be an im-
mune-mediated, organ-specific inflammatory dis-
ease in which intralesional T lymphocytes trigger 
primed basal stem keratinocytes to proliferate and 
perpetuate the disease. It may occur in a number 
of different clinical forms and is usually induced 
by some extrinsic factors (e.g., infection, medi-
cations, physical or emotional stress). Immune 
mechanisms are implicated in the pathogenesis of 
psoriasis, stimulating the proliferation of epidermal 
keratinocytes, the absence of keratinocyte differ-
entiation, and vascular proliferation by the activa-
tion of T lymphocytes and release of TH1 cytokines 
(IL-2, INF-γ, TNF-α, IL-6) and cellular growth fac-
tors (EGF and TGF-α2). In psoriasis, the epider-
mis is 4-6 times thicker than the normal epidermal 
volume, manifesting as acanthosis. Mitotic activity 
of the basal layer cells in psoriatic epidermis is 8-
fold that in normal cells. Due to the reduced kera-
tinocyte cell cycle (from an average of 28 days to 
3-4 days), keratinocytes with preserved nuclei are 
seen in the epidermis (parakeratosis) (1).
 The disease is organ-specific, involving the 
skin, the scalp and the nails, with joint involvement 
in 5%-40% of cases (2). Clinically, psoriasis may 
present in the form of droplike (guttate psoriasis), 
coin-shaped (nummular psoriasis), plaque form, 
or as generalized skin lesions in erythrodermic 
psoriasis. Skin lesions can involve intertriginous 
regions, while pustular psoriasis and psoriasis 
arthropathica are considered severe and specific 
forms of the disease.
 Clinically, psoriatic lesions may vary from mild 
and moderate through severe clinical manifes-
tations that may considerably interfere with the 
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patient's quality of life. There are a number of 
approaches in defining the disease severity. Ac-
cording to one approach, the severity of psoria-
sis is determined according to skin involvement in 
percentage. For example, if more than 10% of the 
skin surface is involved, it is considered a case 
of severe psoriasis. According to an alternative 
approach, in addition to skin involvement in per-
centage, the quality of life impairment and lesion 
localization (e.g., lesions on the skin of the face 
and hands) are also considered in each individual 
patient. 
THE TREATMENT OF PSORIASIS
 The goals of successful treatment of psoriasis 
include the earliest possible control of the disease 
process, reduction of lesion area in the shortest 
time possible, and increase of the time in remis-
sion with minimal side effects. Topical therapy is 
generally administered for mild and localized forms 
of psoriasis, whereas phototherapy and systemic 
therapy are reserved for extensive lesions and 
more severe forms of the disease. However, pho-
totherapy and systemic therapy (and their combi-
nations with topical agents) may also be used in 
mild cases when topical therapy has failed.
 Topical therapy includes corticosteroids, vi-
tamin D3 analogs, retinoids, tars, anthralin, and 
keratolytics, while methotrexate, acitretin, cyclo-
sporine and biological agents are used in systemic 
therapy (3).
 Topical corticosteroids
 Although the mechanism of topical agents used 
in the treatment of psoriasis is different, involve-
ment in the activation of genes for the cytokines 
that regulate inflammation and immune response is 
common to all. Appropriate use of these drugs en-
ables their synergistic efficacy, lower requirements 
of one or both drugs, and reduction of their side 
effects. If appropriately applied, corticosteroids are 
useful in all phases of anti-inflammatory therapy in 
psoriasis, especially as maintenance therapy. Ef-
ficacious management of psoriasis includes differ-
ent drugs, alone or in combination, in sequential 
or rotational course. These drugs are available in 
a variety of formulations, i.e. as cream, ointment, 
lotion, gel and foam. The medium is chosen ac-
cording to the skin regions involved. The medium 
may influence the clinical effect, drug action, and 
patient compliance. Topical corticosteroid prepara-
tions were introduced in dermatologic therapy in 
1952, when hydrocortisone acetate was synthe-
sized. Fluorohydrocortisone became available on 
the market in 1955, to be followed by triamcinolone 
acetonide (1958) and fluorometholone (1959) (4). 
Topical corticosteroids have since remained the 
most widely used topical agents in the manage-
ment of inflammatory dermatoses, including pso-
riasis and atopic dermatitis. These agents have 
proved efficacious, simple for use, acceptable for 
patients, relatively inexpensive, and safe when ap-
propriately applied. When used for the treatment 
of psoriasis, they frequently lead to rapid improve-
ment or regression of skin lesions (4).
 Corticosteroids have anti-inflammatory, anti-
proliferative, immunosuppressive and vasocon-
strictive action. The mechanism of action varies. 
In cellular cytoplasm, corticosteroids bind to the 
corticosteroid receptor to form the steroid-receptor 
complex which translocates into the cell nucleus, 
where it binds as a homodimer to the glucocor-
ticoid-responsive factor in target genes for corti-
costeroids, which either stimulates or inhibits the 
transcription of protein synthesis (5,6).
 Corticosteroids may also exert an indirect effect 
on the target gene transcription by blocking the ef-
fect of other transcription factors. Corticosteroids 
stimulate the level of nuclear inhibitory factor-κBα 
(IκBα) through IκBα gene expression (5). IκBα 
protein acts by binding to nuclear factor-κB (NF-
κB), another transcription regulator, thus blocking 
its migration to the nucleus. Corticosteroids can 
influence transcription of the genes that do not 
contain a receptor responsible for corticosteroids. 
Corticosteroids can inhibit transcription of various 
genes for proinflammatory cytokines including 
interleukin 1 (IL-1), IL-2, IL-6, interferon gamma 
(IFN-γ) and tumor necrosis factor alpha (TNF-α). 
They also appear to be implicated in the stimula-
tion of lymphocyte expression of the genes for the 
production of anti-inflammatory cytokines such as 
transforming growth factor (TGF) and IL-10 (7).
 In the process of regulation of cytokine produc-
tion, corticosteroids are probably involved in the 
control of type 1 helper T cell, and TH1 and TH2 
lymphocyte presence in the skin. The anti-inflam-
matory effect of corticosteroids also includes in-
hibition of capillary dilation and dermal edema as 
well as suppression of endothelial cells and lym-
phocyte function (6). They diminish vascular per-
meability and thus lymphocyte transfer to skin le-
sions. The antiproliferative effect of corticosteroids 
has not yet been fully elucidated; however, they 
seem to be implicated in the blockade of cytokine 
effect expression (5).
 According to the intensity of action, cortico-
steroid preparations are divided into 4 groups 
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(Europe) and into 7 groups (USA), from group 1 of 
high-potency through group 7 of low-potency cor-
ticosteroids (4, 8, 9) (Table 1). This classification 
is based on the vasoconstrictive effect of topical 
corticosteroids on the skin of healthy volunteers. 
Vasoconstriction test (blanching effect), first used in 
1962, is most widely employed to roughly evaluate 
the efficacy of topical corticosteroids (9). The me-
dium containing active (corticosteroid) component 
can greatly modify clinical efficacy and potency of 
Class 1 (superpotent) Betamethasone dipropionate ointment, cream, 0.05% (Diprolene, 
Diprosone)
Clobetasol propionate  ointment, cream,  0.05% (Temovate, Dermoxin)
Diflorasone diacetate ointment, 0.05% (Fluorone, Psorcon)
Halobetasol propionate ointment, cream, 0.05% (Ultravate)
Class 2 (potent) Amcinonide ointment, 0.1% (Cyclocort)
Desoximetasone ointment, cream,  0.25%; gel, 0.05% (Topicort, Ibaril)
Diflorasone diacetate ointment, 0.05% (Florone, Maxiflor)
Fluocinonide ointment, cream, gel, 0.05% (Lidex)
Halcinonide cream, 0.1% (Halog)
Mometasone furoate ointment, 0.1% (Elocon, Ecural)
Triamcinolone acetonide ointment, 0.5% (Kenalog)
Class 3 (potent) Amcinonide cream, lotion 0.1% (Cyclocort)
Betamethasone valerate ointment, 0.01% (Valisone)
Diflorasone diacetate cream, 0.05% (Florone, Maxiflor)
Fluticasone propionate ointment, 0.005% (Cutivate)
Fluocortolone cream, 0.25% (Ultralan)
Fluocinonide cream, 0.05% (Lidex E cream, Topsyn)
Halcinonide ointment, 0.1% (Halog)
Triamcinolone acetonide ointment, 0.1% (Aristocort A)
Triamcinolone acetonide, cream 0.5% (Aristocort-HP)
Class 4 (midstrength) Betamethasone valerate lotion, 0.01% (Valisone, Luxiq)
Desoximetasone cream, gel 0.05% (Topicort-LP)
Fluocinolone acetonide cream, 0.2% (Synalar-HP)
Fluocinolone acetonide ointment, 0.025% (Synalar)
Flurandrenolide ointment, 0.05% (Cordran)
Halcinonide cream, 0.025% (Halog)
Hydrocortisone valerate ointment, 0.2% (Westcort)
Mometasone furoate cream, 0.1% (Elocon, Ecural)
Triamcinolone acetonide ointment 0.1% (Kenalog)
Class 5 (midstrength) Betamethasone dipropionate lotion, 0.05% (Diprosone)
Betamethasone valerate cream, 0.01% (Valisone)
Fluocinolone acetonide cream, 0.025% (Synalar)
Fluocinolone acetonide oil, 0.01% (Dermasmoothe/FS)
Flurandrenolide cream, 0.05% (Cordran)
Fluticasone propionate cream, 0.05% (Cutivate)
Hydrocortisone butyrate cream, 0.1% (Locoid)
Hydrocortisone valerate cream, 0.2% (Westcort)
Triamcinolone acetonide lotion, 0.1% (Kenalog)
Class 6 (mild) Alclometasone dipropionate ointment, cream,  0.05% (Aclovate)
Betamethasone valerate lotion, 0.05% (Valisone)
Desonide cream, 0.05% (Desowen, Tridesilon)
Fluocinolone acetonide cream, solution 0.01% (Synalar)
Prednicarbate 0.1% cream (Dermatop)
Triamcinolone acetonide cream, 0.1% (Aristocort)
Class 7 (least potent) Dexamethasone cream, 0.1% (Decadron phosphate)
Hydrocortisone, 0.5%, 1%, 2.5% (Hytone, and others)
Methylprednisolone, 1% (Medrol)
Topical preparations with flumethasone, prednisolone
Table 1. Potency ranking of selected topical corticosteroid preparations (9)
From: Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 
2006;54(1):1-25 (9).
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the active substance. Particular pharmaceutical 
forms are more appropriate for use on some skin 
regions (e.g., ointment is more suitable for use on 
the palms, feet and other dry skin areas, whereas 
lotion and foam are cosmetically more suitable for 
use on the scalp) (4,9).
 Patient age, type and extension of lesion, and 
the site of lesion should be considered on decid-
ing on the choice and formulation of corticosteroid. 
So, low-potency corticosteroids are reserved for 
the face, inguinal and axillary regions, and for use 
in children. The anatomic site of lesion is of sub-
stantial importance because of different absorp-
tion of topical agents on various skin regions. The 
rate of absorption is 4% on the scalp through 35% 
in the scrotum region. The rate of drug penetra-
tion on eyelids is about 300-fold that on the feet, 
probably entailing a higher probability of unwant-
ed effects. On other skin regions, initial therapy in 
adults usually includes the use of medium-potency 
corticosteroids, whereas high-potency agents are 
employed for thick chronic lichenified plaques on 
the feet and hands (4,9). Therefore, the protocol 
on the use of topical corticosteroids according to 
potency of action should be strictly followed: low- 
and high-potency agents for acute inflammatory 
lesions on the face and in intertriginous regions, 
and high-potency agents for chronic, hyperkera-
totic and lichenified lesions on the hands and feet. 
It is recommended to apply them once or twice a 
day. The use on every other day or on weekends 
is efficient in the management of various chronic 
states. Low-potency corticosteroids are used in 
children and elderly patients (9). For many pa-
tients the intermittent use of topical corticosteroids 
is highly effective.
 Topical preparations produce best therapeutic 
results when inflammatory lesions involve less 
than 20% of the skin surface. In the treatment of 
psoriasis, these have been successfully used in 
combination with acitretin, cyclosporine, metho-
trexate, PUVA, UVB, tazarotene, tar, and dithra-
nol. The optimal use of topical corticosteroids 
implies initial therapy with a potent compound to 
achieve disease control; continuation with a less 
potent preparation after an adequate response 
has been achieved; reduction of the frequency of 
application (alternate-day therapy; weekend use); 
continuation of daily application of the least potent 
preparation; tapering off treatment upon complete 
healing and care in treating children, the elderly 
and treatment at certain locations (e.g., around 
eyes, face, scrotum, flexures) (9).
 Adverse effects of topical corticosteroids
 Although corticosteroids are drugs intended for 
topical application and make the basis of topical 
therapy for psoriasis and inflammatory derma-
toses, their prolonged and excessive use is ac-
companied by numerous undesired side effects. 
Children are especially susceptible to side effects 
because of the great skin surface relative to their 
body mass.
 The prevalence of local side effects is by far 
greater upon topical application of corticosteroids 
than with their systemic use. The use of topical 
corticosteroids can be associated with numerous 
local and systemic side effects.
 Atrophic changes can occur with a prolonged 
use of any topical corticosteroid. The skin turns 
shiny, transparent, with the possible occurrence of 
striae. The factors that determine the grade of skin 
atrophy include age, lesion localization, potency 
of the corticosteroid applied, and use of occlusion. 
Atrophic process begins with microscopic degen-
erative changes in the epidermis with a decrease 
in the cell volume and number of cell layers. It is 
observed in 3-14 days of therapy initiation.
 Histological changes can also be perceived in 
the dermis. Corticosteroids exert an antiprolifera-
tive effect on fibroblasts, leading to reduction in the 
synthesis of collagen and mucopolysaccharides. 
Elastic fiber becomes significantly thinned and 
fragmented, and the skin is sensitive to mechani-
cal force, thus favoring the occurrence of striae. 
While the initial atrophic changes of the skin are 
still reversible alterations, the occurrence of striae 
indicates their transformation to an irreversible 
process (4,9).
 Telangiectasias are abnormally dilated capillar-
ies and arterioles, which occur due to the action of 
microvascular endothelial cells stimulated by cor-
ticosteroids. On the skin affected with telangiec-
tasias even a minor trauma may lead to purpura, 
because of damage to local vasculature.
 The application of potent corticosteroids on fa-
cial skin will nearly always result in exacerbation 
of previous or newly induced dermatoses such as 
rosacea, contact dermatitis, perioral dermatitis, 
and fungal infections (4,9,10). Fungal infections 
frequently occur in association with persisting pso-
riatic lesions. Exacerbation of pustular psoriasis is 
very common upon discontinuation of topical corti-
costeroid therapy, and when it has been used over 
a large skin surface for a prolonged period of time. 
Acneiform eruption has also been reported with the 
use of corticosteroid preparations on facial skin.
Gorgievska Sukarovska and Lipozenčić     Acta Dermatovenerol Croat
Topical management of psoriasis      2006;14(3):188-196 
192 ACTA DERMATOVENEROLOGICA CROATICA
 Inappropriate use of corticosteroids may mask 
the diagnosis of the existing fungal dermatoses 
(9). Tinea incognita is a term that refers to various 
clinical manifestations of mycotic infection, which 
should always be taken in consideration in the 
presence of persisting and relapsing lesions (11).
 Although rarely reported in association with 
topical corticosteroids, hypertrichosis of a vari-
able grade is rather common with the use of sys-
temic corticosteroids. Contact sensitization due to 
topical corticosteroids is recorded in 0.2%-6% of 
cases, mostly manifesting in the form of chronic 
dermatitis unresponsive to the therapy applied, 
or as acute eczema, contact urticaria, acute local 
edema or id-like reaction (10). It should be noted 
that sensitization to active (corticosteroid) compo-
nent and to other ingredients of a topical prepa-
ration has to be distinguished. Cross sensitivity 
among various topical corticosteroids has also 
been demonstrated. Thus, there are 4 groups of 
corticosteroids that help determine contact sensi-
tivity to corticosteroids: group A, hydrocortisone; 
group B, triamcinolone; group C, betamethasone; 
and group D, hydrocortisone butyrate (9). Cortico-
steroid dependence develops when potent cortico-
steroids are continuously used on the skin of the 
face for fear from the eruption of acne, rosacea, 
perioral dermatitis or telangiectasias upon therapy 
discontinuation.
 Tachyphylaxis may also occur after topical cor-
ticosteroid therapy, and is described as the need 
of substituting low-potency corticosteroids by high-
potency agents because the desired effect cannot 
be achieved with the former anymore (4).
 Besides local side effects, topical use of cor-
ticosteroids may also result in systemic side ef-
fects. Systemic side effects generally occur upon 
the application of high-potency corticosteroids 
over a large skin area and for a prolonged period 
of time, however, they have also been described 
with inappropriate use of medium-potency topical 
agents. The changes may be endocrine (Cush-
ing’s disease, centripetal obesity, striae), metabol-
ic (glucose intolerance, osteopathy, aseptic femo-
ral necrosis, adrenocortical suppression, growth 
retardation), electrolyte disbalance (edema, hypo-
calcemia, hypertension), or ocular (cataract, glau-
coma) (9).
 In children, all corticosteroids irrespective of 
their potency can provoke systemic side effects, 
due to the greater skin surface to body mass ratio. 
Suppression of the hypothalamic-pituitary-adrenal 
(HPA) axis has been reported even after the use 
of low- and medium-potency corticosteroids for 3-
4 weeks (4). Children with atopic dermatitis are at 
a high risk of HPA axis suppression because of the 
increased corticosteroid penetration through the 
dermatitis changed skin (9). Growth retardation 
has also been recorded, however, usually of no 
clinical significance, showing complete normaliza-
tion upon therapy discontinuation (4). Therefore, 
great caution is warranted on using corticosteroid 
preparations in children. In England, there is the 
British National Formulary defining the use of these 
drugs in children. Alclometasone dipropionate is 
used in children older than 1 year, mometasone 
furoate in children older than 2 years, fluocinolone 
acetonide oil in children older than 6 years, and 
betamethasone and clobetasone in children older 
than 12 years (9).
 The development of glaucoma due to the use 
of topical corticosteroids is a rare but serious prob-
lem. Vision impairment associated with glaucoma 
has also been described with a prolonged use of 
topical corticosteroids on the skin of the face.
 The risk of HPA axis suppression is increased 
with the use of high-potency topical corticoste-
roids, especially in combination with occlusion. 
The use of low corticosteroid doses (2 g per day 
of 0.05% clobetasol propionate cream) for several 
days can decrease the level of cortisol. Prolonged 
topical application of high-potency corticosteroids 
results in the manifestation of iatrogenic Cushing’s 
syndrome. In rare cases, addisonian crisis asso-
ciated with the use of topical corticosteroids can 
lead to lethal outcome (9).
 In diabetic patients, glycemia is elevated by 
percutaneous absorption of topical corticosteroids. 
It should be noted that the manifestation of latent 
diabetes is also possible. Great caution should be 
exercised when topical corticosteroids are used in 
patients with diabetes, hypertension, impaired liver 
function, glaucoma, or positive tuberculin test (4).
The rate of corticosteroid side effects can be re-
duced and the therapeutic effect of corticosteroids 
in psoriasis patients improved by using a combi-
nation of various drugs to produce a synergistic 
effect (1). Rotational treatment from monotherapy 
through a combination of drugs reduces the cumu-
lative toxicity of drugs; however, topical corticoste-
roids are not used (4). Sequential treatment (two 
drugs) is used in various stages of the disease, 
with step-wise exclusion of the first drug while re-
taining the second drug during the period of main-
tenance therapy (9). Specific drugs used in con-
tinuation to corticosteroid therapy include vitamin 
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D3 analogs, retinoids, and topical immunomodu-
lators. The action of the commonly used agents 
discussed herein, i.e. corticosteroids, topical im-
munomodulators, retinoids and vitamin D analogs, 
occurs through varying and divergent pathways. 
However, common to all of them is that they all 
interface with the transcriptional activation of cyto-
kine genes that control inflammation and immune 
response (5).
 Vitamin D3 analogs in topical therapy  
 Vitamin D3 analogs regulate proliferation and 
differentiation of epidermal keratinocytes. These 
drugs were introduced in therapy with the use of 
calcipotriene at the beginning of the 1990s. Cal-
cipotriene is the only drug from this group that is 
currently available in the USA, whereas in Europe 
calcitriol and tacalcitol are also available (4,5).
 Calcipotriene inhibits proliferation and stimu-
lates terminal differentiation of keratinocytes in 
psoriatic lesions. It binds to vitamin D-selective 
receptor in keratinocyte nuclei. Receptors of this 
type are also found in fibroblasts, T and B lympho-
cytes, monocytes and macrophages. The activa-
tion of these receptors is also likely to play a role in 
the antipsoriatic action of calcipotriene. Similar to 
corticosteroids, it antagonizes the action of other 
factors of transcription such as nuclear factor of T 
lymphocyte activation (NF-AT), thus indirectly re-
ducing cytokine expression (IL-2, IL-6, IL-8, IFN-γ 
and GM-CSF) (5).
 Calcipotriene has been found to be less effi-
cient than class I corticosteroids in topical therapy. 
An initial period is needed for its effect to become 
observable (i.e. its action is relatively slow), and is 
associated with a high incidence of irritative skin 
reactions when applied as topical therapy. When 
used in combination with topical corticosteroid 
agents, their synergistic action has proved efficient 
in the management of psoriasis with better clinical 
results by reducing particular agent toxicity. Also, 
local skin irritation is considerably reduced when 
calcipotriene is used in combination with topical 
corticosteroids. In 1996, 84% of patients were 
treated with calcipotriene (4). It should be noted 
that calcipotriene is relatively unstable in acidic 
medium; therefore its use in combination with 6% 
salicylic preparations, 12% ammonium lactate 
lotion and 0.2% hydrocortisone-17-valerate oint-
ment is discouraged (4).
 Combinations of topical vitamin D3 with 
acitretin, cyclosporine, methotrexate, PUVA and 
UVB, topical corticosteroids, tars, and dithranol 
have proved successful (12). Topical vitamin D3 
analogs such as tacalcitol, calcipotriol, maxacal-
citol and paricalcitol have found wide usage as a 
successful treatment modality for squamous pso-
riasis (12-15).
 Topical retinoids
 Retinoids are vitamin A derivatives that regulate 
cellular growth and differentiation. The only retinoid 
used in topical therapy of psoriasis is tazarotene, 
a third-generation retinoid, available in the form of 
cream and ointment. Tazarotene leads to normal-
ization of keratinocyte differentiation, and reduces 
keratinocyte proliferation as well as inflammation. 
It binds selectively to retinoid receptors (RARs). 
Tazarotene shows high affinity for RAR-β and 
RAR-γ, and low affinity for RAR-α, regulating gene 
transcription directly and indirectly, similar to the 
action of corticosteroids and calcipotriene (5).
 Tazarotene is a retinoid with selective action 
upon β and γ retinoid receptors, and is useful in 
the management of squamous psoriasis. In com-
bination with corticosteroids (alternatively), it also 
efficiently prevents relapses of psoriasis (4). Taz-
arotene has proved efficacious and safe in the 
treatment of psoriasis. Remissions of at least 12 
weeks after therapy discontinuation have been 
recorded. When used as monotherapy, many 
patients develop skin irritation at the site of appli-
cation, known as retinoid dermatitis. Tazarotene 
is compatible with many corticosteroids for topi-
cal use. Combinations of tazarotene and topical 
corticosteroids have proved more efficient and 
tolerable than either monotherapy. A combina-
tion of tazarotene-clobetasol applied on Mondays, 
Wednesdays and Fridays with a corticosteroid on 
Tuesdays and Thursdays resulted in side effect 
reduction as compared with monotherapy (4). The 
use of tazarotene is contraindicated in pregnancy 
because of retinoid teratogenicity.
 Tars, anthralin and keratolytics
 Besides emollients, first-line topical agents 
for mild and moderate forms of psoriasis include 
tars, dithranol and vitamin D3 analogs (4,12,13). 
Topical therapy with phototherapy and/or systemic 
therapy is used in severe and refractory forms of 
psoriasis (4,12).
 Coal tars are topical preparations of lower ef-
ficacy than topical corticosteroids or corticoste-
roids and calcipotriene. They are characterized 
by strong odor, and leave stains on bedclothes 
and clothes. Tars (e.g., anthralin cream 1%) are 
used in combination with UVB rays by the meth-
od of Göckerman. Like coal tars, anthralin is less 
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efficient than corticosteroids, also causing folliculi-
tis and photosensitivity, irritating the skin and leav-
ing stains on clothes. Anthralin is used in combina-
tion with phototherapy (UVB rays) by the method 
of Ingram (short contact therapy), frequently em-
ployed in the management of plaque psoriasis. 
Phototherapy as immunosuppressive therapy is 
one of the oldest approaches to treating psoria-
sis. Narrowband UVB at 311 nm or less effective 
broadband UVB is commonly used for disruption 
of key cells in the pathogenesis of psoriasis.
 Salicylic acid at 3%-10% concentration is the 
most widely used keratolytic. It is used in combi-
nation with topical corticosteroids to remove squa-
mae, thus enabling better corticosteroid penetra-
tion and anti-inflammatory effect. Salicylic acid is 
used initially in the treatment of stationary psoria-
sis. It has also been successfully used in combi-
nation with topical immunomodulators and photo-
therapy (13).
 Topical immunomodulators
 The first immunomodulators were topical corti-
costeroids, used for a half a century. New immu-
nomodulators used in the treatment of psoriasis 
are topical calcineurin inhibitors, tacrolimus and 
pimecrolimus. Tacrolimus and pimecrolimus are 
relatively novel agents in the treatment of in-
flammatory dermatoses. The two agents have a 
similar mechanism of action. They act by inhibi-
tion of calcineurin, an intracellular enzyme that is 
involved in the regulation of gene transcription in 
T lymphocytes. Topical immunomodulators bind 
to macrophillin-12, a cytosol receptor, to form the 
TI-macrophillin complex that precludes dephos-
phorylation of the nuclear factor AT2 (NF-AT2) by 
blocking the production of calcineurin serine phos-
phatase. Thus, the synthesis of Th1 and Th2 type 
inflammatory cytokines is blocked. Topical immu-
nomodulators are also involved in the modification 
of the structure and function of epidermal dendritic 
antigen-presenting cells, thereby reducing their 
ability of T lymphocyte stimulation. Their anti-in-
flammatory action also includes the inhibition of 
histamine release from mastocytes (5,16).
 Immunomodulators were presented in the mid-
1990s: tacrolimus as the first one, and pimecro-
limus soon thereafter, as efficacious alternatives 
to topical corticosteroids in the treatment of atopic 
dermatitis, especially in cases where long-term 
topical therapy is indicated. Tacrolimus is avail-
able as 0.03% and 0.1% ointment, and pimecroli-
mus as 1% cream which can also be used in chil-
dren older than 2 years (5,14,17). These agents 
are ever more widely used in the treatment of 
psoriasis, as shown by numerous studies. Topical 
immunomodulators are also useful in the man-
agement of intertriginous psoriasis (14). Studies 
have demonstrated the efficacy of pimecrolimus 
for psoriasis to improve when used with occlusion. 
Experimental formulations of this agent showed 
greater efficacy than the commercially available 
ones, thus opening new prospects for its use in 
the management of psoriasis (16,17). Pimecroli-
mus 1% cream has been reported to be efficient 
in the treatment of inverse psoriasis, with a rap-
id onset of action and excellent tolerance (16), 
whereas tacrolimus 1% cream has been recom-
mended as the drug of choice for facial psoriatic 
lesions (16,18). A combination of tacrolimus 0.1% 
ointment and 6% salicylic gel proved efficient in 
the treatment of psoriasis (19). The use of a com-
bination of topical immunomodulators and topical 
corticosteroids to reduce the rate of side effects 
has also been reported (4). In a preclinical trial, 
topical sirolimus proved efficient in the treatment 
of psoriasis (20). 
 Discussion on optimal topical therapy of 
psoriasis
 Psoriasis is a chronic relapsing disease quite 
frequently necessitating long-term therapy. More 
than 60% of patients in the USA were on single 
drug therapy (21). One of the approaches to the 
treatment of psoriasis includes the use of com-
bined rotational and sequential therapy. There has 
been increasing emphasis on utilizing combina-
tion treatment regimens to address the complicat-
ed nature of psoriasis management. In combined 
therapy, agents with different mechanisms of ac-
tion are simultaneously used to potentiate their 
additive or synergistic effects, while reducing side 
effects by lowering the dosage of particular agents 
(21). In rotational therapy, different monotherapies 
or combined therapies are alternatively applied 
to reduce cumulative toxicity of particular agents 
(21). Rotational approach may occasionally be 
necessary due to exacerbation of the clinical pic-
ture or local skin irritation. In practice, therapeutic 
switch to rotational approach is performed after 
a prolonged use of a particular therapy, mostly 
months or years (4).
 The goal of sequential therapy is to achieve 
rapid initial improvement of lesions by use of a 
more potent agent, then switching to a less po-
tent drug as maintenance therapy. The treatment 
is performed in three phases: first, clearing phase, 
with potent agents at maximal dosage; second, 
Gorgievska Sukarovska and Lipozenčić     Acta Dermatovenerol Croat
Topical management of psoriasis      2006;14(3):188-196 
195ACTA DERMATOVENEROLOGICA CROATICA
transition phase, with gradual introduction of the 
second drug while gradually reducing the first one; 
and third phase, i.e. continuation of maintenance 
therapy. In practice, so-called pulsed therapy is 
also frequently used, where high-potency cortico-
steroids are usually applied in the initial phase for 
rapid improvement of lesions, then maintenance 
therapy is only applied on particular, predeter-
mined days.
 The efficacy of the combination of topical cor-
ticosteroids and calcipotriene has been clinically 
confirmed (4). When used in combination, these 
agents provide synergistic efficacy in the manage-
ment of psoriasis while reducing the toxicity of par-
ticular drugs and local skin irritation (4). The higher 
efficacy versus monotherapy was verified by the 
application of calcipotriene in the morning with 
halobetasol in the evening. In another study, the 
same regimen was used for 2 weeks, followed by 
pulsed therapy with halobetasol during weekends 
and with calcipotriene on week days. This regimen 
yielded higher efficacy than monotherapy (5).
 A combination of corticosteroid dermatologic 
agents and tazarotene also leads to improved effi-
cacy and local tolerability as compared with mono-
therapies. A combination of tazarotene with the cor-
ticosteroids mometasone (medium potency) and 
fluocinonide (high potency) proved more efficient 
than the combination with a low-potency corticoste-
roid (5). In comparison with tazarotene monother-
apy, combined therapy with tazarotene-clobetasol 
propionate on Mondays, Wednesdays and Fridays, 
and a corticosteroid on Tuesdays and Thursdays 
led to reduction of psoriasis relapses (4).
 Studies have recently focused on the possible 
combinations of topical corticosteroids with topi-
cal calcineurin inhibitors. This treatment modality 
has been verified in the management of atopic 
dermatitis. Tacrolimus in combination with the 
medium-potency chlorocortolone pivalate proved 
more efficient than monotherapy in various lesions 
(excoriation, induration, erythema, lichenification, 
pruritus and burning sensation) (4). In vitro stud-
ies have demonstrated that a combination of be-
tamethasone valerate in the form of foam with ta-
crolimus ointment or pimecrolimus cream results 
in better penetration of calcineurin inhibitors. This 
is of special relevance for tacrolimus in the light of 
its rather poor skin penetration (4). Using thera-
pies in rotational or intermittent fashion reduces 
the toxicity to any organ. The strategy may include 
so-called “treatment holidays” until relapse of the 
disease is achieved (intermittent therapy) (22).
 CONCLUSION
 Psoriasis is a complex disease that requires 
safe long-term therapy. Clinical management is 
currently dictated by physical, psychological as-
pects of the disease, with historic response to 
therapy and aspects identified as mild to severe. 
In many patients, intermittent therapy with topical 
corticosteroids is most efficacious. The use of po-
tent topical corticosteroids is discouraged in resis-
tant cases and on sensitive skin areas. The opti-
mal use of topical corticosteroids consists of initial 
administration of potent agents to achieve efficient 
control of the disease, followed by the use of less 
potent agents. It is reasonable to reduce the fre-
quency of corticosteroid application by skipping it 
on particular days or by use of weekend therapy. 
Caution is warranted with the use of corticoste-
roids in children and elderly patients, especially on 
sensitive skin regions such as the face, scrotum, 
intertriginous area, periocular area, etc.
 Several novel medications have challenged 
traditional treatment paradigms and created new 
issues on decision-making. Some therapeutic reg-
imens can be continuously used for a prolonged 
period of time; however, intermittent therapy for 
several months at the most is generally required. 
Selective glucocorticoid agonists (ligands), cur-
rently in the phase of preclinical trials, may prove 
most efficient. Combinations of drugs adminis-
tered according to a sequential or rotational pro-
tocol and various combinations of topical and sys-
temic medications have proved successful and 
minimize the rate of adverse effects of any medi-
cation. However, individual approach is absolutely 
necessary in each patient with psoriasis.
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